Top drug safety twitter this week

What drug safety topics are of interest this week? I've been keeping up to date with this on twitter to see what is going on and what articles/stories tweeters are finding interesting.

Top tweeters:

@damienveauvy focussed on the importance of effective reporting methods by consumers for reported adverse reactions to medicines. This article on reporting system for the general public was in a WHO report on the safety monitoring of medicinal products.

@AngelAzpeitia looked into how the new pharmacovigilance legislation will impact not only European companies but US drug manufacturers too. As I've discussed before, the aim of the PV Legislation is to increase ease of access to information and greater transparency to improve the safety of human medicines. Of particular interest to the US market with operations in Europe is the Investigational New Drug (IND) Final Rule and the New Drug Application (NDA) Final Rule and manufacturing supply chain regulations.

And finally, @herbalprof posted an interesting link to an article looking into the risk benefit profile of statins. The article looked into the JUPITER study (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) to look into the risk of new onset diabetes vs the benefits of the drug.

Leave a Reply

Your email address will not be published. Required fields are marked *